Select Bibliography

Filter by any of these (after searching):

AUTHOR ABSTRACT DEADLINES

A meeting abstract must be submitted by the first or corresponding author to the Alliance Publications Coordinator (publications@AllianceNCTN.org) at least two weeks prior to the meeting abstract submission deadline. For detailed information about Alliance Publications guidelines, please refer to the policies, along with the author abstract deadlines.

There are 92 items

A phase 3 study of androgen annihilation in high-risk biochemically relapsed prostate cancer: an Alliance Foundation trial (AFT-19)

Aggarwal, Rahul , Eggener, Scott , Chen, Ronald , Heller, Glenn ... - ASCO - J Clin Oncol - 2018

Abstract - No-Endpoint - Trial-Description-Only - GU - AFT-19

The Effect of Prior Androgen Synthesis Inhibition on Outcomes of Subsequent Therapy with Docetaxel in Patients with Metastatic Castrate Resistant Prostate Cancer: Results from a Retrospective Analysis of a Randomized Phase 3 Clinical Trial (CALGB 90401) (Alliance)

Aggarwal, Rahul , Halabi, Susan , Kelly, William Kevin ... - - Cancer - 2013

Manuscript - Secondary-not-in-original - Primary - GU - CALGB-90401

Management of Recurrent Prostate Cancer after Radiotherapy: Long-term results from CALGB 9687, a Contemporary Prospective Multi-institutional Salvage Prostatectomy Series

Al-Daghmin, A , Sokoloff, MH , Halabi, S , Sanford, BL , Eastham, JA ... - AUA - J Urology - 2014

Abstract - Primary - Long-Term-Followup - GU - CALGB-9687

Prognostic Model for Predicting Survival of Patients With Metastatic Urothelial Cancer Treated With Cisplatin-Based Chemotherapy

Apolo, Andrea B. , Ostrovnaya, Irina , Halabi, Susan ... - - J. Natl. Cancer Inst - 2013

Manuscript - Secondary-not-in-original - Primary - GU - CALGB-90102

External validation of prognostic models for overall survival (OS) in patients (pts) with advanced cancer (UC) treated with cisplatin-based chemotherapy.

Apolo, Andrea Borghese , Philips, George , Ostrovnaya, Irina ... - ASCO - J. Clin. Oncol. - 2012

Abstract - Secondary-not-in-original - Primary - GU - CALGB-90102

Alliance A031501: Phase III Randomized Adjuvant Study of MK-3475 (Pembrolizumab) in Muscle Invasive and Locally Advanced Urothelial Carcinoma (MIBC) (AMBASSADOR) vs Observation

Apolo, Andrea , Rosenberg, Jonathan , Morris, Michael ... - ASCO GU - J Clin Oncol - 2019

Abstract - No-Endpoint - Trial-Description-Only - GU - A031501

Arsenic trioxide in recurrent urothelial cancer: a cancer and leukemia group B phase II trial (CALGB 99903).

Bajorin, Dean F , Halabi, Susan ... - - Clin Genitourin Cancer - 2009

Manuscript - Primary - Primary - GU - CALGB-99903

Impact of therapy on genomics and transcriptomics in high-risk prostate cancer treated with neoadjuvant docetaxel and androgen deprivation therapy

Beltran, Himisha , Wyatt, Alexander W , Chedgy, Edmund C ... - - Clin. Cancer Res. - 2017

Manuscript - Secondary-not-in-original - Primary - GU - CALGB-90203

Quality-adjusted time without symptoms or toxicity (Q-TWiST): analysis of cabozantinib versus sunitinib in patients with advanced renal cell carcinoma of intermediate or poor risk (Alliance A031203)

Chen, RC , Feuilly, M , Meng, J , Lister, J , Marteau, F , Morris, M ... - ASCO - J Clin Oncol - 2018

Abstract - Secondary-not-in-original - Primary - GU - A031203

Quality‐adjusted survival with first‐line cabozantinib or sunitinib for advanced renal cell carcinoma in the CABOSUN randomized clinical trial (Alliance)

Chen, Ronald C. , Choueiri, Toni K. , Feuilly, Marion , Meng, Jie ... - - Cancer - 2020

Manuscript - Secondary-not-in-original - Primary - GU - A031203

PD-L1 status and clinical outcomes to cabozantinib, sunitinib and everolimus in patients with metastatic clear-cell RCC treated on CABOSUN and METEOR clinical trials

Choueiri, T.K. , Flaifel, A. , Xie, W. , Braun, D. , Ficial, M. ... - ESMO - Annal Oncol - 2018

Abstract - Secondary-not-in-original - Primary - GU - A031203

Cabozantinib Versus Sunitinib As Initial Targeted Therapy for Patients With Metastatic Renal Cell Carcinoma of Poor or Intermediate Risk: The Alliance A031203 CABOSUN Trial

Choueiri, Toni K. , Halabi, Susan , Sanford, Ben L. , Hahn, Olwen ... - - J. Clin. Oncol - 2017

Manuscript - Primary - Primary - GU - A031203

CABOzantinib versus SUNitinib (CABOSUN) as initial targeted therapy for patients with metastatic renal cell carcinoma (mRCC) of poor and intermediate risk groups: results from ALLIANCE A031203 Trial.

Choueiri, Toni K. , Halabi, Susan , Sanford, Ben L. , Hahn, Olwen ... - ESMO - - 2016

Abstract - Primary - Primary - GU - A031203

Progression-free survival (PFS) by independent review results from ALLIANCE A031203 trial (CABOSUN): cabozantinib versus sunitinib as initial targeted therapy for patients (pts) with metastatic renal cell carcinoma (mRCC)

Choueiri, Toni K. , Hessel, Colin , Halabi, Susan , Sanford, Ben ... - ESMO - Ann Oncol - 2017

Abstract - Primary - Primary - GU - A031203

Cabozantinib versus sunitinib as initial therapy for metastatic renal cell carcinoma of intermediate or poor risk (Alliance A031203 CABOSUN randomised trial): Progression-free survival by independent review and overall survival update

Choueiri, Toni K. , Hessel, Colin , Halabi, Susan , Sanford, Ben ... - - Eur. J. Cancer - 2018

Manuscript - Secondary - Primary - GU - A031203

p53 Protein Expression Status and Recurrence in Men Treated With Radiation Therapy and Androgen Suppression Therapy for Higher Risk Prostate Cancer: A Prospective Phase II Cancer and Leukemia Group B Study

D'Amico, A. V. , Halabi, S. , Vollmer, R. , Loffredo, M. , Mcmahon, E. ... - - Int. J. Radiat. Oncol. Biol. Phys. - 2007

Abstract - Primary - Primary - GU - CALGB-159807 , CALGB-9682

Tumor volume changes on 1.5 tesla endorectal MRI during neoadjuvant androgen suppression therapy for higher-risk prostate cancer and recurrence in men treated using radiation therapy results of the phase II CALGB 9682 study

D'Amico, Anthony V. , Halabi, Susan , Tempany, Clare ... - - Int J Radiat Oncol Biol Phys - 2008

Manuscript - Secondary - Primary - GU - CALGB-9682

p53 protein expression status and recurrence in men treated with radiation and androgen suppression therapy for higher-risk prostate cancer: a prospective phase II Cancer and Leukemia Group B Study (CALGB 9682).

D'Amico, Anthony V , Halabi, Susan , Vollmer, Robin ... - - Urology - 2008

Manuscript - Secondary - Primary - GU - CALGB-159807 , CALGB-9682

A phase II study of estramustine, docetaxel, and exisulind in patients with hormone- refractory prostate cancer: results of cancer and leukemia group B trial 90004.

Dawson, Nancy A , Halabi, Susan , Ou, San-San , Biggs, David D ... - - Clin Genitourin Cancer - 2008

Manuscript - Primary - Primary - GU - CALGB-90004

CALGB 90203 (Alliance): Radical Prostatectomy with or without neoadjuvant chemohormonal therapy in men with clinically localized, high risk prostate cancer.

Eastham, J.A. , Heller, G. , Halabi, S. , Monk, J. P. , Beltran, H. ... - AUA - Journal of Urology - 2019

Abstract - Primary - Primary - GU - CALGB-90203

CALGB 90203 (Alliance): Radical Prostatectomy with or without neoadjuvant chemohormonal therapy in men with clinically localized, high risk prostate cancer

Eastham, J.A. , Heller, G. , Halabi, S. , Monk, J. P. , Beltran, H. ... - ASCO - J. Clin. Oncol. - 2019

Abstract - Primary - Primary - GU - CALGB-90203

Cancer and Leukemia Group B 90203 (Alliance): Radical Prostatectomy With or Without Neoadjuvant Chemohormonal Therapy in Localized, High-Risk Prostate Cancer

Eastham, James A. , Heller, Glenn , Halabi, Susan ... - - J. Clin. Oncol - 2020

Manuscript - Primary - Primary - GU - CALGB-90203

Baseline testosterone levels in men with clinically localized high-risk prostate cancer treated with radical prostatectomy with or without neoadjuvant chemohormonal therapy (Alliance)

Eastham, James A. , Heller, Glenn , Hillman, David W. ... - - J Urol - 2021

Manuscript - Secondary-not-in-original - Primary - GU - CALGB-90203

ECOG score analysis as a proxy for health-related quality of life assessment in patients with poor or intermediate risk metastatic renal cell carcinoma from the CABOSUN trial (Alliance A031203)

Feldman, D , Feuilly, M , Meng, J , Lister, J , Marteau, F , Morris, MJ ... - ASCO - J Clin Oncol - 2018

Abstract - Secondary-not-in-original - Primary - GU - A031203

Cabozantinib Versus Sunitinib for Untreated Patients with Advanced Renal Cell Carcinoma of Intermediate or Poor Risk: Subgroup Analysis of the Alliance A031203 CABOSUN trial

George, Daniel J. , Hessel, Colin , Halabi, Susan ... - - Oncologist - 2019

Manuscript - Secondary - Primary - GU - A031203

The prognostic significance of plasma interleukin-6 levels in patients with metastatic hormone-refractory prostate cancer: results from Cancer and Leukemia Group B 9480.

George, Daniel J , Halabi, Susan , Shepard, Timothy F , Sanford, Ben ... - - Clin. Cancer Res. - 2005

Manuscript - Primary - Primary - GU - INT-0159

Cabozantinib versus sunitinib for previously untreated patients with advanced renal cell carcinoma (RCC) of intermediate or poor risk: subgroup analysis of progression-free survival (PFS) and objective response rate (ORR) in the Alliance A031203 CABOSUN trial

George, Daniel , Hessel, Colin , Halabi, Susan , Sanford, Ben ... - ASCO GU - J Clin Oncol - 2018

Abstract - Secondary-not-in-original - Primary - GU - A031203

Relationship of opioid analgesic (OA) use at 3 months and overall survival in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC)

Halabi, S. , Kelly, W. K. , Kaplan, E. B. ... - ASCO - J. Clin. Oncol. - 2012

Abstract - Secondary-not-in-original - Primary - GU - CALGB-90401

A novel intermediate endpoint for predicting overall survival in men with metastatic castration-recurrent prostate cancer (CRPC)

Halabi, S. , Ou, S. , Vogelzang, N. J. , Scher, H. I. ... - ASCO - J. Clin. Oncol. - 2007

Abstract - Secondary-not-in-original - Comprehensive - GU - Comprehensive

Is progression free survival a predictor of overall survival in men with castration recurrent prostate cancer (CRPC)?

Halabi, S. , Ou, S. , Vogelzang, N. J. ... - ASCO GU - - 2008

Abstract - Secondary-not-in-original - Meta-Analysis - GU - C9181 , C9182 , CALGB-90004 , CALGB-90006 , CALGB-9583 , CALGB-9680 , CALGB-9780 , CALGB-99813 , INT-0159

Use of progression-free survival (PFS) to predict overall survival (OS) in patients with metastatic renal cell carcinoma (mRCC)

Halabi, S. , Rini, B. I. , Stadler, W. M. , Archer, L. E. ... - ASCO - J. Clin. Oncol. - 2010

Abstract - Secondary-not-in-original - Primary - GU - CALGB-90206

Pain interference scores at 6-weeks from baseline and overall survival (OS) in men with metastatic castration-resistant prostate cancer (mCRPC)

Halabi, S. , Vogelzang, N. J. , Kornblith, A. B. , Archer, L. E. ... - ASCO GU - Genitourinary Cancers Symposium - 2009

Abstract - Secondary-not-in-original - Primary - GU - C9181 , C9182 , INT-0159

Identification of prognostic and predictive biomarkers of overall survival (OS) and progression-free survival (PFS) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) treated with docetaxel, prednisone (DP) +/- bevacizumab (B) in CALGB 90401 (Alliance)

Halabi, S , Yang, Q. , Starr, Mark D , Brady, John C , Armstrong, A.J. ... - ASCO GU - J Clin Oncol - 2021

Abstract - Secondary-not-in-original - Primary - GU - CALGB-90401

Meta-Analysis Evaluating the Impact of Site of Metastasis on Overall Survival in Men With Castration-Resistant Prostate Cancer

Halabi, Susan , Kelly, William Kevin , Ma, Hua , Zhou, Haojin ... - - J. Clin. Oncol - 2016

Manuscript - Secondary-not-in-original - Meta-Analysis - GU - CALGB-90601

The site of visceral metastases (mets) to predict overall survival (OS) in castration-resistant prostate cancer (CRPC) patients (pts): A meta-analysis of five phase III trials.

Halabi, Susan , Kelly, William Kevin , Zhou, Haojin ... - ASCO - J. Clin. Oncol. - 2014

Abstract - Secondary-not-in-original - Meta-Analysis - GU - CALGB-90401 , S9916

Updated Prognostic Model for Predicting Overall Survival in First-Line Chemotherapy for Patients With Metastatic Castration-Resistant Prostate Cancer

Halabi, Susan , Lin, Chen-Yen , Kelly, W. Kevin , Fizazi, Karim S. ... - - J. Clin. Oncol - 2014

Manuscript - Secondary-not-in-original - Primary - GU - CALGB-90401

A prognostic model for predicting overall survival in metastatic castrate-resistant prostate cancer (mCRPC) men treated with second-line chemotherapy

Halabi, Susan , Lin, Chen-Yen , Small, Eric J. , Armstrong, Andrew J. ... - ASCO - J. Clin. Oncol. - 2013

Abstract - Secondary-not-in-original - Primary - GU - CALGB-90401

Inverse correlation between body mass index and clinical outcomes in men with advanced castration-recurrent prostate cancer.

Halabi, Susan , Ou, San-San , Vogelzang, Nicholas J ... - - Cancer - 2007

Manuscript - Secondary-not-in-original - Meta-Analysis - GU - C9181 , C9182 , CALGB-90004 , CALGB-90006 , CALGB-9583 , CALGB-9680 , CALGB-9780 , CALGB-99813

Progression-Free Survival (PFS) as a Surrogate Endpoint of Overall Survival (OS) in Patients with Metastatic Renal Cell Carcinoma (mRCC)

Halabi, Susan , Rini, Brian , Escudier, Bernard , Stadler, Walter M. ... - - Cancer - 2014

Manuscript - Secondary-not-in-original - Primary - GU - CALGB-90206

Progression-Free Survival as a Predictor of Overall Survival in Men With Castrate-Resistant Prostate Cancer

Halabi, Susan , Vogelzang, Nicholas J. , Ou, San-San , Owzar, Kouros ... - - J Clin Oncol - 2009

Manuscript - Secondary-not-in-original - Comprehensive - GU - Comprehensive

Pain predicts overall survival in men with metastatic castration-refractory prostate cancer.

Halabi, Susan , Vogelzang, Nicholas J , Kornblith, Alice B ... - - J. Clin. Oncol. - 2008

Manuscript - Secondary-not-in-original - Comprehensive - GU - CALGB-9840 , C9181 , C9182

The impact of prior radical prostatectomy in men with metastatic castration recurrent prostate cancer: a pooled analysis of 9 Cancer and Leukemia Group B Trials.

Halabi, Susan , Vogelzang, Nicholas J , Ou, San-San ... - - J. Urol. - 2007

Manuscript - Secondary-not-in-original - Meta-Analysis - GU - C9181 , C9182 , CALGB-90004 , CALGB-9000 , CALGB-9583 , CALGB-9680 , CALGB-9780 , CALGB-99813 , INT-0159

Evaluating the effect of tobacco on prostate cancer outcomes with VEGF-targeted therapy

Harzstark, A. L. , Halabi, S. , Kelly, W. K. , Morris, M. J. ... - ASCO - J. Clin. Oncol. - 2012

Abstract - Secondary-not-in-original - Primary - GU - CALGB-90401

Hypertension is associated with clinical outcome for patients (Pts) with metastatic renal cell carcinoma (RCC) treated with interferon and bevacizumab on CALGB 90206

Harzstark, A. L. , Halabi, S. , Stadler, W. M. , Vaena, D. A. ... - ASCO GU - Genitourinary Cancers Symposium - 2010

Abstract - Secondary-not-in-original - Primary - GU - CALGB-90206

Implementing a Geriatric Assessment in Cooperative Group Clinical Cancer Trials: CALGB 360401

Hurria, Arti , Cirrincione, Constance T. , Muss, Hyman B. ... - - J Clin Oncol - 2011

Manuscript - Primary - Primary - GU - CALGB-360401 , CALGB-99809

Combination external beam radiation and brachytherapy boost with androgen deprivation for treatment of intermediate-risk prostate cancer: long-term results of CALGB 99809

Hurwitz, M. D. , Halabi, S. , Archer, L. , Mcginnis, L. S. ... - - Cancer - 2011

Manuscript - Primary - Primary - GU - CALGB-99809

Combination external beam radiation and brachytherapy boost with androgen suppression for treatment of intermediate-risk prostate cancer: an initial report of CALGB 99809.

Hurwitz, Mark D , Halabi, Susan , Ou, San-San , McGinnis, Lamar S ... - - Int. J. Radiat. Oncol. Biol. Phys. - 2008

Manuscript - Primary - Preliminary - GU - CALGB-99809

A tomato-based, lycopene-containing intervention for androgen-independent prostate cancer: results of a Phase II study from the North Central Cancer Treatment Group.

Jatoi, Aminah , Burch, Patrick , Hillman, David , Vanyo, Joanne M ... - - Urology - 2007

Manuscript - Secondary-not-in-original - Primary - GU - N0351

Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer: results of the Cancer and Leukemia Group B 9182 study.

Kantoff, P W , Halabi, S , Conaway, M , Picus, J , Kirshner, J ... - - J. Clin. Oncol. - 1999

Manuscript - Primary - Primary - GU - C9182

Five-year follow-up of a multicenter phase II study of neoadjuvant paclitaxel, estramustine phosphate, and carboplatin (TEC) plus androgen-deprivation therapy (ADT) prior to radiation therapy in patients with unfavorable-risk localized prostate cancer: CALGB 99811

Kelly, W. K. , Halabi, S. , Archer, L. E. , Bogart, J. A. ... - ASCO GU - Genitourinary Cancers Symposium - 2010

Abstract - Primary - Long-Term-Followup - GU - CALGB-99811

Liver metastases (LM) to predict for short overall survival (OS) in metastatic castration-resistant prostate cancer (mCRPC) patients (pts)

Kelly, W. K. , Halabi, S. , Carducci, M. A. , George, D. J. ... - ASCO - J. Clin. Oncol. - 2012

Abstract - Secondary-not-in-original - Primary - GU - CALGB-90401

A randomized double-blind placebo controlled phase III trial comparing docetaxel, prednisone and placebo with docetaxel prednisone and bevacizumab in men with metastatic castrate resistant prostate cancer (metCRPC): Survival results of CALGB 90401

Kelly, W. K. , Halabi, S. , George, D. J. , Stadler, W. M. ... - ASCO - J. Clin. Oncol. - 2010

Abstract - Primary - Primary - GU - CALGB-90401

Randomized, Double-Blind, Placebo-Controlled Phase III Trial Comparing Docetaxel and Prednisone With or Without Bevacizumab in Men With Metastatic Castration-Resistant Prostate Cancer: CALGB 90401

Kelly, William Kevin , Halabi, Susan , Carducci, Michael ... - - J. Clin. Oncol - 2012

Manuscript - Primary - Primary - GU - CALGB-90401

Multicenter phase 2 study of neoadjuvant paclitaxel, estramustine phosphate, and carboplatin plus androgen deprivation before radiation therapy in patients with unfavorable-risk localized prostate cancer: results of Cancer and Leukemia Group B 99811.

Kelly, William Kevin , Halabi, Susan , Elfiky, Aymen , Ou, San-San ... - - Cancer - 2008

Manuscript - Primary - Primary - GU - CALGB-99811

A Molecular Model for Predicting Overall Survival in Patients with Metastatic Clear Cell Renal Carcinoma: Results from CALGB 90206 (Alliance)

Kim, Hyung L. , Halabi, Susan , Li, Ping , Mayhew, Greg , Simko, Jeff ... - - EBioMedicine - 2015

Manuscript - Secondary-not-in-original - Primary - GU - CALGB-150603 , CALGB-90206

A prognostic model for overall survival in patients with metastatic clear cell renal carcinoma: Results from CALGB 90206 (Alliance)

Kim, Hyung L. , Halabi, Susan , Li, Ping , Mayhew, Greg , Simko, Jeff ... - AUA - J Urol - 2015

Abstract - Secondary-not-in-original - Primary - GU - CALGB-90206

Prognostic and predictive tumor-based biomarkers in patients (pts) with advanced renal cell carcinoma (RCC) treated with interferon alpha (IFN) with or without bevacizumab (Bev): Results from CALGB (Alliance) 90206

Kluger, Harriet M. , Halabi, Susan , Solomon, Nicole C ... - ASCO - J. Clin. Oncol. - 2014

Abstract - Secondary-not-in-original - Primary - GU - CALGB-90206

A randomized trial of radium-223 dichloride and cabozantinib in patients with advanced renal cell carcinoma (RCC) with bone metastases (RADICAL / Alliance A031801)

McKay, Rana R. , Jacene, Heather , Atherton, Pamela ... - ASCO - J Clin Oncol - 2021

Abstract - No-Endpoint - Trial-Description-Only - GU - A031801

Management of recurrent prostate cancer after radiotherapy: long-term results from CALGB 9687 (Alliance), a prospective multi-institutional salvage prostatectomy series

Mohler, James L. , Halabi, Susan , Ryan, Stephen T. , Al-Daghmin, Ali ... - - Prostate Cancer Prostatic Dis. - 2019

Manuscript - Primary - Long-Term-Followup - GU - CALGB-9687

Efficacy of peripheral androgen blockade in prostate cancer patients with biochemical failure after definitive local therapy: Results of Cancer and Leukemia Group B (CALGB) 9782

Monk, J.P. , Halabi, S. , Picus, J. , Hussain, A. , Philips, G. ... - - Cancer - 2012

Manuscript - Primary - Primary - GU - CALGB-9782

Alliance A031201: A phase III trial of enzalutamide (ENZ) versus enzalutamide, abiraterone, and prednisone (ENZ/AAP) for metastatic castration resistant prostate cancer (mCRPC)

Morris, Michael J. , Heller, Glenn , Bryce, Alan , Armstrong, Andrew ... - ASCO - J Clin Oncol - 2019

Abstract - Primary - Primary - GU - A031201

Identification of predictive biomarkers of overall survival (OS) in patients (pts) with advanced renal cell carcinoma (RCC) treated with interferon alpha (I) with or without bevacizumab (B): Results from CALGB 90206 (Alliance)

Nixon, A. B. , Halabi, S. , Shterev, I. , Starr, M. D. , Brady, J. C. ... - ASCO - J. Clin. Oncol. - 2013

Abstract - Secondary - Primary - GU - C90206

Bevacizumab and risk of arterial and venous thromboembolism in metastatic castration-resistant prostate cancer patients treated on Cancer and Leukemia Group B (CALGB) 90401 (Alliance)

Patel, Jai N. , Jiang, Chen , Hertz, Daniel L. , Mulkey, Flora A. ... - - Cancer - 2015

Manuscript - Secondary-not-in-original - Primary - GU - CALGB-90401

Bevacizumab (BEV) and risk of hemorrhage (HEM) in metastatic castration-resistant prostate cancer (mCRPC) patients treated on CALGB 90401 (Alliance).

Patel, Jai Narendra , Jiang, Chen , Hertz, Daniel Louis ... - ASCO - J. Clin. Oncol. - 2014

Abstract - Secondary-not-in-original - Primary - GU - CALGB-90401

A phase II trial of cisplatin (C), gemcitabine (G) and gefitinib for advanced urothelial tract carcinoma: results of Cancer and Leukemia Group B (CALGB) 90102

Philips, G. K. , Halabi, S. , Sanford, B. L. , Bajorin, D. ... - - Ann Oncol - 2009

Manuscript - Primary - Primary - GU - CALGB-90102

Long term efficacy of peripheral androgen blockade on prostate cancer: CALGB 9782.

Picus, J. , Halabi, S. , Small, E. , Hussain, A. , Philips, G. ... - - J. Clin. Oncol. - 2006

Abstract - Primary - Primary - GU - CALGB-9782

A Phase II Study Of Estramustine, Docetaxel, And Bevacizumab In Men With Castrate Resistant Prostate Cancer: Results Of Cancer And Leukemia Group B (CALGB) 90006

Picus, Joel , Halabi, Susan , Kelly, W. Kevin ... - - Cancer - 2011

Manuscript - Primary - Primary - GU - CALGB-90006

Alliance A031902 (CASPAR): A randomized, phase III trial of enzalutamide (ENZ) with rucaparib (RUCA)/placebo (PBO) as novel therapy in first-line metastatic castration-resistant prostate cancer (mCRPC).

Rao, Arpit , Heller, Glenn , Ryan, Charles J. ... - ASCO GU - J Clin Oncol - 2022

Abstract - No-Endpoint - Trial-Description-Only - GU - A031902

CASPAR (Alliance A031902) - A Randomized, Phase III Trial of Enzalutamide with/without Rucaparib as a Novel Therapy in First-Line Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Rao, Arpit , Ryan, Charles J , Vanderweele, David , Heller, Glenn ... - ASCO GU - J Clin Oncol - 2021

Abstract - No-Endpoint - Trial-Description-Only - GU - A031902

Efficacy of carboplatin–taxane combinations in the management of castration-resistant prostate cancer: a pooled analysis of seven prospective clinical trials

Regan, M. M. , O'Donnell, E. K. , Kelly, W. K. , Halabi, S. ... - - Ann Oncol - 2010

Manuscript - Secondary-not-in-original - Comprehensive - GU - CALGB-99813

CALGB 90206: A phase III trial of bevacizumab plus interferon-alpha versus interferon-alpha monotherapy in metastatic renal cell carcinoma

Rini, B. I. , Halabi, S. , Rosenberg, J. E. , Stadler, W. M. ... - ASCO GU - Genitourinary Cancers Symposium - 2008

Abstract - Primary - Preliminary - GU - CALGB-90206

Bevacizumab plus interferon-alpha versus interferon-alpha monotherapy in patients with metastatic renal cell carcinoma: Results of overall survival for CALGB 90206

Rini, B. I. , Halabi, S. , Rosenberg, J. E. , Stadler, W. M. ... - ASCO - J. Clin. Oncol. - 2009

Abstract - Primary - Primary - GU - CALGB-90206

Phase III Trial of Bevacizumab Plus Interferon Alfa Versus Interferon Alfa Monotherapy in Patients With Metastatic Renal Cell Carcinoma: Final Results of CALGB 90206

Rini, Brian I. , Halabi, Susan , Rosenberg, Jonathan E. ... - - J Clin Oncol - 2010

Manuscript - Primary - Primary - GU - CALGB-90206

Bevacizumab Plus Interferon Alfa Compared With Interferon Alfa Monotherapy in Patients With Metastatic Renal Cell Carcinoma: CALGB 90206

Rini, Brian I. , Halabi, Susan , Rosenberg, Jonathan E. ... - - J Clin Oncol - 2008

Manuscript - Primary - Preliminary - GU - CALGB-90206

Phase II study of bortezomib in patients with previously treated advanced urothelial tract transitional cell carcinoma: CALGB 90207

Rosenberg, J. E. , Halabi, S. , Sanford, B. L. , Himelstein, A. L. ... - - Ann. Oncol - 2008

Manuscript - Primary - Primary - GU - CALGB-90207

Randomized Phase III Trial of Gemcitabine and Cisplatin With Bevacizumab or Placebo in Patients With Advanced Urothelial Carcinoma: Results of CALGB 90601 (Alliance)

Rosenberg, Jonathan E. , Ballman, Karla A. , Halabi, Susan ... - - J Clin Oncol - 2021

Manuscript - Primary - Primary - GU - CALGB-90601

CALGB 90601 (Alliance): Randomized, double blind, placebo-controlled phase III trial comparing gemcitabine and cisplatin with bevacizumab or placebo in patients with metastatic urothelial carcinoma

Rosenberg, Jonathan , Ballman, Karla , Halabi, Susan , Watt, Colleen ... - ASCO - J Clin Oncol - 2019

Abstract - Primary - Primary - GU - CALGB-90601

Androgens and Overall Survival in Metastatic Castration-Resistant Prostate Cancer Patients Treated with Docetaxel

Ryan, Charles J , Dutta, Sandipan , Kelly, William K ... - - Clin Genitourin Cancer - 2020

Manuscript - Secondary-not-in-original - Primary - GU - CALGB-90401

Serum Androgens and Survival in metastatic Castration Resistant Prostate Cancer (mCRPC) Patients Treated with Docetaxel and Prednisone: Results from CALGB 90401 (Alliance)

Ryan, Charles J , Dutta, Sandipan , Kelly, William K ... - ASCO - J. Clin. Oncol. - 2017

Abstract - Secondary-not-in-original - Primary - GU - CALGB-90401

Androgen Decline and Survival During Docetaxel Therapy in metastatic Castration Resistant Prostate Cancer (mCRPC)

Ryan, Charles J , Dutta, Sandipan , Kelly, William K , Russell, Carly ... - - Prostate Cancer Prostatic Dis. - 2020

Manuscript - Secondary-not-in-original - Primary - GU - CALGB-90401

Decline in serumandrogens and survival in metastatic castration resistant prostate cancer (mCRPC) patients treated with docetaxel and prednisone: results from CALGB 90401 (Alliance)

Ryan, Charles J , Dutta, Sandipan , Kelly, William K , Russell, Carly ... - EAU - Eur Urol - 2018

Abstract - Secondary-not-in-original - Primary - GU - CALGB-90401

Adrenal androgen levels as predictors of outcome in prostate cancer patients treated with ketoconazole plus antiandrogen withdrawal: results from a cancer and leukemia group B study.

Ryan, Charles J , Halabi, Susan , Ou, San-San , Vogelzang, Nicholas J ... - - Clin. Cancer Res. - 2007

Manuscript - Secondary-not-in-original - Primary - GU - CALGB-9583

The impact of prior therapy with ketoconazole (keto) on clinical outcomes after subsequent docetaxel treatment in metastatic castration-resistant prostate cancer (mCRPC) patients: Results from a randomized phase III trial (CALGB 90401).

Small, E. J. , Halabi, S. , Carducci, M. A. , Ryan, C. J. ... - ASCO - J. Clin. Oncol. - 2012

Abstract - Secondary-not-in-original - Primary - GU - CALGB-90401

Antiandrogen withdrawal alone or in combination with ketoconazole in androgen-independent prostate cancer patients: a phase III trial (CALGB 9583).

Small, Eric J , Halabi, Susan , Dawson, Nancy A , Stadler, Walter M ... - - J. Clin. Oncol. - 2004

Manuscript - Primary - Primary - GU - CALGB-9583

Efficacy and safety of zoledronic acid in men with castration-sensitive prostate cancer and bone metastases: Results of CALGB 90202 (Alliance)

Smith, M. R. , Halabi, S. , Ryan, C. J. , Stadler, W. M. , Hussain, A. ... - ASCO GU - J. Clin. Oncol. - 2013

Abstract - Primary - Primary - GU - CALGB-90202

Randomized Controlled Trial of Early Zoledronic Acid in Men With Castration-Sensitive Prostate Cancer and Bone Metastases: Results of CALGB 90202 (Alliance)

Smith, Matthew R. , Halabi, Susan , Ryan, Charles J. , Hussain, Arif ... - - J. Clin. Oncol - 2014

Manuscript - Primary - Primary - GU - CALGB-90202

Management of recurrent prostate cancer after radiotherapy: Results from CALGB 9687, a contemporary prospective multi-institutional salvage radical prostatectomy series

Sokoloff, M. H. , Steinberg, G. D. , Halabi, S. , Sanford, B. L. ... - AUA - J Urol - 2008

Abstract - Primary - Primary - GU - CALGB-9687

Impact of a multi-disciplinary patient education session on accrual to a difficult clinical trial: the Toronto experience with the surgical prostatectomy versus interstitial radiation intervention trial.

Wallace, Kris , Fleshner, Neil , Jewett, Michael , Basiuk, Joan ... - - J. Clin. Oncol. - 2006

Manuscript - Secondary-not-in-original - Primary - GU - Z0070

PDIGREE: An adaptive phase 3 trial of PD-inhibitor nivolumab and Ipilimumab (IPI-NIVO) with VEGF TKI cabozantinib (CABO) in metastatic untreated REnal Cell CancEr (Alliance A031704)

Zhang, Tian , Ballman, Karla , Choudhury, Atish , Chen, Ronald C. ... - ASCO GU - J Clin Oncol - 2021

Abstract - No-Endpoint - Trial-Description-Only - GU - A031704

PDIGREE: An adaptive phase 3 trial of PD-inhibitor nivolumab and Ipilimumab (IPI-NIVO) with VEGF TKI cabozantinib (CABO) in metastatic untreated REnal Cell CancEr (Alliance A031704)

Zhang, Tian , Ballman, Karla , Choudhury, Atish , Chen, Ronald C. ... - ASCO - J Clin Oncol - 2020

Abstract - No-Endpoint - Trial-Description-Only - GU - A031704

PDIGREE: An adaptive phase 3 trial of PD-inhibitor nivolumab and Ipilimumab (IPI-NIVO) with VEGF TKI cabozantinib (CABO) in metastatic untreated REnal Cell CancEr (Alliance A031704)

Zhang, Tian , Ballman, Karla , Choudhury, Atish , Chen, Ronald C. ... - ASCO - J Clin Oncol - 2019

Abstract - No-Endpoint - Trial-Description-Only - GU - A031704

PDIGREE: An adaptive phase 3 trial of PD-inhibitor nivolumab and Ipilimumab (IPI-NIVO) with VEGF TKI cabozantinib (CABO) in metastatic untreated REnal Cell CancEr (Alliance A031704)

Zhang, Tian , Ballman, Karla , Choudhury, Atish , Chen, Ronald C. ... - IKCS - J Clin Oncol - 2020

Abstract - No-Endpoint - Trial-Description-Only - GU - A031704